KRAS and colorectal carcinoma: In summary, both in vivo and in vitro studies indicate that 4-AAQB may be an important therapeutic agent that targets KRAS-mutant CRC cells through the reduction of the Ras-signaling cascade and modulation of the expression of key miRs in CRC tumorigenesis.